- Home
- IOBT vs KALA Comparison
IOBT vs KALA Comparison
Compare IOBT & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- KALA
- Stock Information
- Founded
- IOBT 2014
- KALA 2009
- Country
- IOBT Denmark
- KALA United States
- Employees
- IOBT N/A
- KALA N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- KALA Health Care
- Exchange
- IOBT Nasdaq
- KALA Nasdaq
- Market Cap
- IOBT 31.7M
- KALA 26.2M
- IPO Year
- IOBT 2021
- KALA 2017
- Fundamental
- Price
- IOBT $0.52
- KALA $1.54
- Analyst Decision
- IOBT Hold
- KALA Buy
- Analyst Count
- IOBT 3
- KALA 3
- Target Price
- IOBT $4.00
- KALA $31.50
- AVG Volume (30 Days)
- IOBT 4.6M
- KALA 2.7M
- Earning Date
- IOBT 11-11-2025
- KALA 11-11-2025
- Dividend Yield
- IOBT N/A
- KALA N/A
- EPS Growth
- IOBT N/A
- KALA N/A
- EPS
- IOBT N/A
- KALA N/A
- Revenue
- IOBT N/A
- KALA N/A
- Revenue This Year
- IOBT N/A
- KALA N/A
- Revenue Next Year
- IOBT N/A
- KALA N/A
- P/E Ratio
- IOBT N/A
- KALA N/A
- Revenue Growth
- IOBT N/A
- KALA N/A
- 52 Week Low
- IOBT $0.32
- KALA $1.10
- 52 Week High
- IOBT $2.79
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- IOBT 27.94
- KALA 27.81
- Support Level
- IOBT $0.45
- KALA $1.50
- Resistance Level
- IOBT $0.55
- KALA $1.70
- Average True Range (ATR)
- IOBT 0.08
- KALA 0.91
- MACD
- IOBT -0.06
- KALA -1.43
- Stochastic Oscillator
- IOBT 14.13
- KALA 2.36
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.